In the future, the dialysis provider will rely on innovative technologies in the People's Republic and will accept one-off costs of 110 million euros.
AI-generated summary
FMC has been operating in China for more than two decades and generates around 6 to 7 percent of sales in the Care Enablement segment.
The dialysis provider Fresenius Medical Care (FMC) is realigning its long-standing business in China. The DAX group wants to concentrate more on innovative technologies for blood washing in treatment centers and intensive care in the People's Republic. At the same time, the portfolio will be adapted to local requirements, announced FMC in Bad Homburg.
This change in strategy will incur one-off costs of 110 million euros. They would be reported as special items and are expected to be recorded in the third quarter of 2026.
With the new portfolio, the company is “ideally positioned” to strengthen its competitive position in China and take advantage of long-term growth opportunities there, the company explained. Specifically, FMC plans to introduce several modern technologies for blood washing in the country, including a system for high-volume hemodiafiltration. FMC is currently rolling out similar technology in the USA; the system is considered more effective and faster in dialysis. In return, the sales and production of older dialysis systems in China will be ended.
According to the information, FMC has been operating in China for more than two decades. The People's Republic contributes around 6 to 7 percent of sales in the Care Enablement segment, in which the group bundles its product business.
AI outlook — possibilities, not facts
Recording of one-off costs of 110 million euros in the third quarter of 2026
Very likely · Within months

After chaotic conditions and overcrowded shuttles to the Grünheide gigafactory, Tesla deployed security personnel on buses. Plant management and the works council are demanding more discipline from the workforce when dealing with voluntary company services.

The federal government and the state of Hesse are withdrawing completely from the Condor airline. The British majority shareholder Attestor will take over the remaining 49 percent shares in August 2027 by exercising a purchase option.

Former Amazon executives have analyzed 20 management techniques of the US company in the book “The Secret Playbook”. The Handelsblatt exclusively highlights which methods can be successfully transferred to other companies and what the limits are.

The Düsseldorf-based insurance group Ergo is appointing the head of its US subsidiary Next Insurance, Guy Goldstein, to the board as Chief Artificial Intelligence Officer on October 1st. He replaces Mark Klein, who is leaving the company.

Novo Nordisk's capital market day in London disappoints investors despite plans for new blockbusters by 2030. The share continues to lose value, while US competitor Eli Lilly dominates with strong profit growth.

UBS Real Estate GmbH handles the open real estate fund UBS Euroinvest for German private investors. The reason for the termination on September 24th are ongoing challenges in the European real estate market and ongoing capital withdrawals.